Fig. 1: Isolation of sarbecovirus-neutralizing antibody GW01 from COVID-19 patients. | Cell Discovery

Fig. 1: Isolation of sarbecovirus-neutralizing antibody GW01 from COVID-19 patients.

From: Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses

Fig. 1: Isolation of sarbecovirus-neutralizing antibody GW01 from COVID-19 patients.The alternative text for this image may have been generated using AI.

a Binding of five mAbs isolated from COVID-19 patients to the RBD proteins of SARS-CoV-2, RaTG13, GD-Pangolin, GX-Pangolin, and SARS-CoV in ELISA. b Binding affinity of GW01 to RBD proteins of SARS-CoV-2, RaTG13, GD-Pangolin, GX-Pangolin, or SARS-CoV was measured by bilayer interferometry experiments. c Neutralization of mAbs against pseudovirus of SARS-CoV-2 and its variants B.1.1.7, B.1.351, B.1.617.1, B.1.617.2, B.1.1.529, and C.37, SARS-CoV, and bat SARSr-CoVs (WIV1 and Rs3367). d Neutralization summary of GW01, S309, and other NAbs against pseudoviruses. e Neutralization of GW01 against authentic SARS-CoV-2 and its variants B.1.1.7, B.1.351, B.1.617.2, and B.1.525. f Neutralization of GW01 against authentic bat SARSr-CoVs (WIV1 and SHC014). g IC50s of GW01 against seven authentic viruses.

Back to article page